Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 17  |  Issue : 3  |  Page : 644-651

BCL6B hypermethylation predicts metastasis and poor prognosis in early-stage hepatocellular carcinoma after thermal ablation


1 Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China
2 Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China
3 Department of Interventional Radiology, Affiliated Hospital of Qingdao University, Qingdao, China
4 aDepartment of Ultrasound, Yantai Qishan Hospital, Yantai, China
5 Department of Ultrasound, The First Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, China

Correspondence Address:
Jie Yu
Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing
China
Ping Liang
Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.JCRT_1504_20

Rights and Permissions

Aims: The aim of this study was to evaluate the role of BCL6B methylation in the progression of early-stage hepatocellular carcinoma (HCC) after thermal ablation. Settings and Design: This is a retrospective study and written informed consent was obtained from all patients or their legal guardians. Subjects and Methods: Between October 2008 and December 2013, 73 patients with early-stage HCC within the Milan criteria, who received thermal ablation, were recruited. Statistical Analysis Used: Based on methylation-specific polymerase chain reaction, the relationship between BCL6B methylation and patient characteristics and prognosis was analyzed using univariate, multivariate, and Kaplan–Meier analysis. Results: The median follow-up period was 56 (8–110) months. For the BCL6B unmethylated group, the 1-, 3- and 5-year metastasis and overall survival (OS) rates after thermal ablation were 10.0%, 10.0%, and 40.0% and 100%, 100% and 90.0%, respectively. The 1-, 3-, and 5-year metastasis and OS rates of the methylated group were 23.8%, 66.7% and 88.9% and 66.2%, 71.4% and 41.3%, respectively. Levels of absolute count lymphocyte, serum cholinesterase and albumin in the BCL6B unmethylated group were higher than those in the methylated group (P = 0.020, 0.000, and 0.009, respectively). Kaplan–Meier analysis revealed that BCL6B methylation was related to metastasis and poor prognosis (P = 0.001 and 0.018, respectively). Univariate analysis revealed that BCL6B methylation was a risk factor for metastasis and poor prognosis (odds ratio [OR]: 5.663; 95% confidence interval [CI], 1.745–18.375, P = 0.004 and OR: 3.734; 95% CI, 1.151–12.110, P = 0.028, respectively). Multivariate analysis revealed that BCL6B methylation was an independent risk factor for metastasis (OR: 3.736; 95% CI, 1.000–13.963,P = 0.05) and not for prognosis (OR: 2.780; 95% CI, 0.835–9.250,P = 0.096). Conclusions: BCL6B methylation could be a valuable prognostic factor for metastasis and poor prognosis in early-stage HCC after thermal ablation, which is an independent risk factor for metastasis. Our findings provide insights for combining ablation and epigenetic therapy for patients with HCC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed296    
    Printed0    
    Emailed0    
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal